ELTP (Elite Pharmaceuticals) Cyclically Adjusted Revenue per Share: $0.04 (As of Mar. 2026)


ELTP Elite Pharmaceuticals Inc ELTP
55 GF Score
Price $0.34
GF Value $0.56
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Elite Pharmaceuticals Cyclically Adjusted Revenue per Share?

Elite Pharmaceuticals ELTP -5.20% 55 Cyclically Adjusted Revenue per Share is $0.04 as of Mar. 2026. GuruFocus rates ELTP with a GF Score™ of 55/100 and a GF Value™ of $0.56 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Elite Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was $0.034. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.04 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Elite Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 33.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 26.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 27.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Elite Pharmaceuticals was 44.20% per year. The lowest was -30.70% per year. And the median was -9.10% per year.

As of today (2026-07-05), Elite Pharmaceuticals's current stock price is $0.341. Elite Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.04. Elite Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 8.53.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Elite Pharmaceuticals was 24.73. The lowest was 1.45. And the median was 5.02.


Elite Pharmaceuticals  (OTCPK:ELTP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Elite Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.341/0.04
=8.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Elite Pharmaceuticals was 24.73. The lowest was 1.45. And the median was 5.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Elite Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Elite Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Elite Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.03 0.03 0.04

Elite Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.04 0.04 0.04

ELTP vs EBS, NIKA, EOLS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


ELTP
55GF Score
Elite Pharmaceuticals Inc ELTP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Elite Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.034/330.2130*330.2130
=0.034

Current CPI (Mar. 2026) = 330.2130.

Elite Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.005 241.018 0.007
201609 0.003 241.428 0.004
201612 0.003 241.432 0.004
201703 0.001 243.801 0.001
201706 0.002 244.955 0.003
201709 0.002 246.819 0.003
201712 0.003 246.524 0.004
201803 0.002 249.554 0.003
201806 0.003 251.989 0.004
201809 0.002 252.439 0.003
201812 0.003 251.233 0.004
201903 0.002 254.202 0.003
201906 0.004 256.143 0.005
201909 0.006 256.759 0.008
201912 0.006 256.974 0.008
202003 0.003 258.115 0.004
202006 0.008 257.797 0.010
202009 0.008 260.280 0.010
202012 0.006 260.474 0.008
202103 0.004 264.877 0.005
202106 0.007 271.696 0.009
202109 0.008 274.310 0.010
202112 0.009 278.802 0.011
202203 0.008 287.504 0.009
202206 0.008 296.311 0.009
202209 0.008 296.808 0.009
202212 0.009 296.797 0.010
202303 0.009 301.836 0.010
202306 0.009 305.109 0.010
202309 0.014 307.789 0.015
202312 0.015 306.746 0.016
202403 0.017 312.332 0.018
202406 0.017 314.175 0.018
202409 0.018 315.301 0.019
202412 0.013 315.605 0.014
202503 0.030 319.799 0.031
202506 0.038 322.561 0.039
202509 0.032 324.800 0.033
202512 0.028 324.054 0.029
202603 0.034 330.213 0.034

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.04 mean?
Elite Pharmaceuticals (ELTP) has a Cyclically Adjusted Revenue per Share of $0.04 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Elite Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $0.04. Overall, Elite Pharmaceuticals has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to EBS and NIKA?
Elite Pharmaceuticals' Cyclically Adjusted Revenue per Share of $0.04 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.56, compared to a current price of $0.34 — trading 39.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.04. Elite Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Cyclically Adjusted Revenue per Share is $0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.34 is trading 39.1% below its estimated GF Value™ of $0.56. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • Cyclically Adjusted Revenue per Share: $0.04
  • GF Value™: $0.56 vs. price of $0.34 (39.1% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
55GF Score

Get the complete analysis for ELTP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$0.56
GF Value